Immutep Limited ADR Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
17.1%projected annual EPS growth
Analyst Coverage
1analyst covering
FY EPS (est.)
-$0.21next fiscal year
Monitoring Framework
Key Performance Indicators
Cash, cash equivalents and term deposits Quarterly110.6MTarget: Maintain sufficient runway to fund operations into H1 CY2028
IMP761 Phase I Trial Progress QuarterlyTarget: Complete Multiple Ascending Dose (MAD) phase in Q3 CY2026
TACTI-004 Phase III Trial Wind-down and Root Cause Analysis QuarterlyTarget: Complete comprehensive root cause analysis by Q3 CY2026
Watch Items
- TACTI-004 Root Cause Analysis ResultsTrigger: Identification of specific patient subgroup underperformance or biomarker mismatchesAction: Reassess the clinical development strategy for eftilagimod alfa (efti) in first-line non-small cell lung cancer (1L NSCLC) and other oncology indications.
- IMP761 Phase I MAD Safety and PK DataTrigger: Completion of MAD phase with favorable safety and pharmacokinetics supporting once-monthly dosingAction: Initiate planning and partner discussions for Phase II clinical trials in targeted autoimmune indications.
- Nasdaq Minimum Bid Price ComplianceTrigger: Stock price remaining below USD 1.00 for consecutive trading days leading to deficiency noticeAction: Monitor share price performance and evaluate corporate actions (such as a reverse share split) to regain compliance if necessary.
Research as of 19 Jun 2026